ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Clinical Trial: 18129

Trial Status: Open
Trial Types: NSCLC, Lung cancer
Disease Type: Lung
Trial ID 18129
Sponsor ID

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location

Locations

Fairfax Office

Learn More About This Trial
Other Relevant Trials
Trial ID APG1252SU101
Sponsor ID

A Multi-Center, Phase I/II Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID U31402-A-U201
Sponsor ID HERTHENA-Lung01

A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location